Celebrex
E474932
Celebrex is a prescription nonsteroidal anti-inflammatory drug (NSAID) used to relieve pain and inflammation in conditions such as arthritis.
Statements (51)
| Predicate | Object |
|---|---|
| instanceOf |
nonsteroidal anti-inflammatory drug
ⓘ
pharmaceutical drug ⓘ prescription medication ⓘ |
| associatedWithRisk |
cardiovascular thrombotic events
ⓘ
gastrointestinal bleeding ⓘ gastrointestinal ulceration ⓘ myocardial infarction ⓘ renal toxicity ⓘ stroke ⓘ |
| belongsToClass | COX-2 selective NSAID ⓘ |
| contraindicatedIn |
patients with aspirin-sensitive asthma triad
ⓘ
patients with history of NSAID-induced asthma ⓘ patients with sulfonamide allergy ⓘ |
| developedBy | G.D. Searle & Company NERFINISHED ⓘ |
| dosageForm | capsule ⓘ |
| eliminationRoute |
fecal
ⓘ
renal ⓘ |
| hasActiveIngredient | celecoxib ⓘ |
| hasGenericName | celecoxib ⓘ |
| hasTradeName | Celebrex NERFINISHED ⓘ |
| indicatedFor |
arthritis-associated pain
ⓘ
menstrual pain ⓘ short-term management of acute pain ⓘ |
| legalStatus | prescription-only medicine ⓘ |
| marketedBy | Pfizer NERFINISHED ⓘ |
| mayCause |
abdominal pain
ⓘ
diarrhea ⓘ dyspepsia ⓘ edema ⓘ hypertension ⓘ |
| mechanismOfAction | selective COX-2 inhibition ⓘ |
| metabolism | hepatic ⓘ |
| metabolizedBy | CYP2C9 NERFINISHED ⓘ |
| onsetOfAction | within a few hours ⓘ |
| pregnancyCategory | may cause fetal risk (late pregnancy) ⓘ |
| reduces | prostaglandin synthesis ⓘ |
| regulatedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| regulatesEnzyme | cyclooxygenase-2 ⓘ |
| relieves |
inflammation
ⓘ
joint stiffness ⓘ pain ⓘ swelling ⓘ |
| requires | prescription ⓘ |
| routeOfAdministration | oral ⓘ |
| treats |
acute pain
ⓘ
ankylosing spondylitis ⓘ juvenile rheumatoid arthritis ⓘ osteoarthritis ⓘ primary dysmenorrhea ⓘ rheumatoid arthritis ⓘ |
| usedFor | long-term management of arthritis pain ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.